rare-disease - The Bright Side

The Bright Side

Sign in Subscribe

rare-disease

A collection of 6 posts

FDA Fast-Tracks Treatment for Fatal Genetic Brain Disease

FDA Fast-Tracks Treatment for Fatal Genetic Brain Disease

FDA Fast-Tracks Treatment for Fatal Genetic Brain Disease Alexander Disease Drug Receives Priority Review Status The FDA has granted Priority Review designation to zilganersen, a potential treatment for Alexander disease — a rare, fatal genetic disorder that affects the brain and nervous system. This designation expedites the review process for treatments

Breakthrough Treatment for Rare Eye Disease Shows Exceptional Results

Breakthrough Treatment for Rare Eye Disease Shows Exceptional Results

Breakthrough Treatment for Rare Eye Disease Shows Exceptional Results Elegrobart Achieves 54-63% Response Rates for Thyroid Eye Disease For patients suffering from thyroid eye disease — a rare but devastating condition that can cause vision problems and facial disfigurement — Viridian Therapeutics has announced breakthrough Phase 3 trial results that offer genuine

Groundbreaking Skin Treatment Shows 100% Response Rate

Groundbreaking Skin Treatment Shows 100% Response Rate

Groundbreaking Skin Treatment Shows 100% Response Rate ENV-294 Delivers Exceptional Results for Severe Eczema Patients In remarkable Phase 1b trial results that have surprised even researchers, Enveda's experimental treatment ENV-294 achieved a 100% response rate in patients with moderate to severe atopic dermatitis — a condition that affects millions

FDA Approves First Brain-Penetrating Treatment for Hunter Syndrome in 20 Years

FDA Approves First Brain-Penetrating Treatment for Hunter Syndrome in 20 Years

In a landmark achievement that could transform treatment for thousands of families affected by rare genetic diseases, the FDA has approved AVLAYAH (tividenofusp alfa-eknm), the first medicine designed...

FDA Approves AVLAYAH: First Hunter Syndrome Treatment to Cross Blood-Brain Barrier

FDA Approves AVLAYAH: First Hunter Syndrome Treatment to Cross Blood-Brain Barrier

FDA Approves AVLAYAH: First Hunter Syndrome Treatment to Cross Blood-Brain Barrier Revolutionary therapy overcomes 20-year treatment gap for rare genetic disease The US Food and Drug Administration has granted accelerated approval to AVLAYAH™ (tividenofusp-alfa-eknm), marking a watershed moment in rare disease treatment. This is the first FDA-approved biologic specifically designed

Breakthrough Gene Therapy Shows Promise for Children With Muscular Dystrophy

Breakthrough Gene Therapy Shows Promise for Children With Muscular Dystrophy

Early clinical results demonstrate significant muscle improvement in limb-girdle muscular dystrophy patients